Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
62 hedge funds and large institutions have $8.05M invested in Zynerba Pharmaceuticals, Inc in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 8 increasing their positions, 26 reducing their positions, and 18 closing their positions.
6% less funds holding
Funds holding: 66 → 62 (-4)
17% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 18
58% less call options, than puts
Call options by funds: $351K | Put options by funds: $843K
66% less capital invested
Capital invested by funds: $23.7M → $8.05M (-$15.7M)
69% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.52M |
| 2 |
Renaissance Technologies
New York
|
+$1.01M |
| 3 |
JP Morgan Chase
New York
|
+$786K |
| 4 |
SIM
Spark Investment Management
New York
|
+$548K |
| 5 |
PP
PDT Partners
New York
|
+$292K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.11M |
| 2 |
FTIOP
Fiduciary Trust International of Pennsylvania
Radnor,
Pennsylvania
|
-$1.65M |
| 3 |
Millennium Management
New York
|
-$675K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$649K |
| 5 |
CCA
Cruiser Capital Advisors
Stamford,
Connecticut
|
-$301K |
ZYNE Hedge Fund Activity: Q4 2018 in Review
62 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q4 2018, worth a combined $8.05M — down 66% from $23.7M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ZYNE and 15 opened new positions — a net loss of 3 holders — while 26 trimmed existing stakes and 8 added.
The largest buyer was Deutsche Bank, adding an estimated $1.52M. The largest seller was Vanguard Group, cutting an estimated $2.11M.
- 62 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q4 2018, down from 66 in Q3 2018.
- Funds reported $8.05M of Zynerba Pharmaceuticals, Inc stock for Q4 2018, down 66% quarter-over-quarter.
- 15 funds opened new Zynerba Pharmaceuticals, Inc positions in Q4 2018 and 18 closed out, a net change of -3 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q4 2018 was Deutsche Bank, an estimated $1.52M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q4 2018 was Vanguard Group, an estimated $2.11M sold.
Based on aggregated 13F filings for Q4 2018.